Biosimilar rituximab, marketed in Argentina as Novex, is subject to an active pharmacovigilance program that, according to Argentine law, must periodically report its status and results to regulatory authorities. In a recent study, researchers examined pharmacovigilance reports to compare the safety profile of biosimilar rituximab with that of its reference.
Biosimilar rituximab, marketed by Laboratorio Elea in Argentina as Novex, is subject to an active pharmacovigilance program that, according to Argentine law, must periodically report its status and results to regulatory authorities. In a study published in the June 7, 2017 issue of Hematological Oncology, researchers examined these pharmacovigilance reports in an effort to compare the safety profile of biosimilar rituximab with that of its reference.
A prospective treatment registry has been in place since the launch of the rituximab biosimilar. Prescribers are directed to report the age, gender, treatment start date, related pathology, dosing, and dose frequency for each patient receiving the biosimilar treatment. After a pre-determined period of time, physicians report treatment outcomes and occurrences of adverse events. For each adverse event, treating physicians file Individual Case Safety Reports (ICSRs).
Between November 26, 2014, to February 28, 2017, physicians registered a total of 584 patients who had been prescribed the biosimilar rituximab for non-Hodgkin’s Lymphoma. Among this group, 378 patients had at least 1 follow-up and were included in the analysis.
The median treatment duration was 214 days (interquartile range: 155 to 306). A mean of 5.7 cycles of rituximab were administered (range: 1 to 12). The total number of ICSRs filed was 15, and the occurrence rate was 1 ICSR filed per 100 cycles administered. Among adverse events reported on ICSRs, 10 were reported as being serious.
The adverse events reported are as follows (1 ICSR reported 2 events):
The researchers concluded that the biosimilar rituximab product demonstrated a safety profile similar to that of the reference product, and that the 2 products had comparable tolerability. The researchers further noted that the pharmacovigilance program showed great value in allowing for continuous monitoring of biosimilar product safety.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Annual STADA Report Shows Record Profit Growth for 2023
March 25th 2024Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.